medigraphic.com
ISSN 0301-696X (Print)
Órgano de difusión del Servicio de Sanidad Militar y del Colegio Nacional de Médicos Militares

2018, Number 5-6

<< Back Next >>

Rev Sanid Milit Mex 2018; 72 (5-6)

Assessment of the variability of the cardiac frequency in patients with systemic arterial hypertension treated through renal ablation by radio frequency. Series of cases

Galván VCG, Hernández JL, Martín HP, Silva RJA, Mendoza RBJ, Romo CX, Rapalo CDN

Language: Spanish
References: 24
Page: 317-323
PDF size: 216.35 Kb.


ABSTRACT

Introduction: Refractory systemic arterial hypertension is the blood pressure above the appropriate goal despite the use of three or more antihypertensive drugs, one of which is a diuretic; renal denervation by radiofrequency ablation, is a treatment for this condition, which is effective and safe. We consider that denervation decreases the tone of the autonomic nervous system at the renal level (renin angiotensin aldosterone axis), so that the result will be a decrease in blood pressure without affecting the variability of the heart rate. Objective: To determine if there is a change in the variability of heart rate in patients with refractory systemic arterial hypertension who are treated by radiofrequency renal denervation with catheter. Material and methods: Observational, descriptive and analytical study of patients with refractory systemic arterial hypertension who were treated by radiofrequency renal ablation with catheter. The variability of the heart rate in the temporal and frequency domain was measured before and two months after the procedure. The statistical analysis of results was by Student’s t-test for related samples. Results: Nine patients were eligible, only six patients with refractory systemic arterial hypertension treated by radiofrequency renal ablation were included, in the domain temporal domain for the standard deviation of the NN intervals (SDNN), a statistically non-significant increase was observed (7 ms, p = 0.58). Conclusion: In the six patients with refractory systemic arterial hypertension treated by radiofrequency renal ablation, it was observed two months after the procedure, that the variability of the heart rate in the time domain for the standard deviation of the NN intervals (SDNN), it increased 7 ms, being statistically non-significant (p = 0.58).


REFERENCES

  1. Instituto Nacional de Salud Pública [INSP]. [2012]. Encuesta Nacional de Salud y Nutrición (ENSANUT) 2012.

  2. Secretaría de Salud [SSA]. Norma Oficial Mexicana para la prevención, tratamiento, y control de la hipertensión arterial sistémica. 2009. (NOM-030-SSA2-2009).

  3. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31 (7): 1281-1357.

  4. Heart Rate Variability, Standars of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and The North American Society of Pacing and Electrophysiology. European Heart Journal. 1996; 17: 354-381.

  5. Ewen S, Ukena C, Böhm M. Percutaneous Renal Denervation: new treatment option for resistant hypertension and more? Hypertension 2013; 99: 1129-1134.

  6. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005; 289: R633-641.

  7. Schlaich MP, Straznicky N, Grima M et al. Renal denervation: a potential new treatment modality for polyciystic ovary syndrome. J Hypertens. 2011; 29: 991-996.

  8. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009; 54: 690-697.

  9. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011; 100: 1049-1057.

  10. Krum H, Schlaich M, Sobotka PA. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281.

  11. Schlaich M, Socratous F, Henebry S. Sympathetic activation in chronic heart failure. J Am Soc Nephrol. 2009; 20: 933-939.

  12. DiBona GF. Neurogenic regulation of renal tubular sodium reabsortion. Am J Physiol. 1977; 233: F73-81.

  13. Grassi G, Quarti-Trevano, Seravalle G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011; 57: 846-851.

  14. Chakko S, Mulingtapang RF. Alteration in heart rate variability and its circadian rhythm in hypertensive patients with left ventricular hypertrophy free or coronary artery disease. Am Heart J. 1993; 126: 1364-1372.

  15. Esler MD, Krum H, Sobotka PA. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN2 Trial): a randomised controlled trial. Lancet. 2010; 376: 1903-1909.

  16. A de la Sierra, DA Calhoun, E Vinyoles, JR Banegas. Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. J Human Hypertens. 2014; 28: 416-420.

  17. Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol. 2001; 38: 1902-1911.

  18. Gil RK, Pedret CC, Ramos J. Variabilidad de la frecuencia cardiaca: concepto, medidas y relación con aspectos clínicos. Arch Med del Deporte. 2008; 123 (XXV): 41-47.

  19. Bhatt DL, Kandzari DE, O’Neill W. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014; 370: 1393-1401.

  20. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012; 380: 778.

  21. Schmieder RE. Hypertension: How should data from SYMPLICITY HTN-3 be interpreted? Nat Rev Cardiol. 2014; 11: 375-376.

  22. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med. 2002; 162: 2313-2321.

  23. Himmel F, Weil J. Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J Clin Hypertens. 2012; 14 (9): 654-655.

  24. Ojeda DJ, Berumen D, Gutiérrez L. Protocolo del manejo de la hipertensión arterial refractaria mediante ablación renal con radiofrecuencia por cateterismo arterial vía femoral. Experiencia del Hospital Central Militar. Rev Sanid Milit. 2013; 67 (1): 1-5.




2020     |     www.medigraphic.com